Literature DB >> 29700075

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform.

Hiddo J L Heerspink1, Vlado Perkovic2.   

Abstract

Entities:  

Keywords:  Cardiovascular Diseases; Chronic; Diabetic Nephropathies; Disease Progression; Humans; Mortality; Personalized Medicine; Platform Trial; Premature; Prevalence; Renal Insufficiency; diabetic nephropathy; kidney; nephrology; randomized controlled trials

Mesh：

Year:  2018        PMID： 29700075      PMCID： PMC5989668          DOI： 10.2215/CJN.01290118

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  7 in total

1.  A novel approach for establishing cardiovascular drug efficacy.

Authors:  Hiddo J Lambers Heerspink; Diederick E Grobbee; Dick de Zeeuw
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Adaptive Randomization of Neratinib in Early Breast Cancer.

Authors:  John W Park; Minetta C Liu; Douglas Yee; Christina Yau; Laura J van 't Veer; W Fraser Symmans; Melissa Paoloni; Jane Perlmutter; Nola M Hylton; Michael Hogarth; Angela DeMichele; Meredith B Buxton; A Jo Chien; Anne M Wallace; Judy C Boughey; Tufia C Haddad; Stephen Y Chui; Kathleen A Kemmer; Henry G Kaplan; Claudine Isaacs; Rita Nanda; Debasish Tripathy; Kathy S Albain; Kirsten K Edmiston; Anthony D Elias; Donald W Northfelt; Lajos Pusztai; Stacy L Moulder; Julie E Lang; Rebecca K Viscusi; David M Euhus; Barbara B Haley; Qamar J Khan; William C Wood; Michelle Melisko; Richard Schwab; Teresa Helsten; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Laura J Esserman; Donald A Berry
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

Review 3.  Unmet need in diabetic nephropathy: failed drugs or trials?

Authors:  Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Lancet Diabetes Endocrinol       Date:  2016-05-06       Impact factor: 32.069

4.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Authors:  Janet Woodcock; Lisa M LaVange
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

5.  Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative.

Authors:  Allison Tong; Jonathan C Craig; Evi V Nagler; Wim Van Biesen
Journal:  Nephrol Dial Transplant       Date:  2017-12-01       Impact factor: 5.992

6.  Fostering innovation, advancing patient safety: the kidney health initiative.

Authors:  Patrick Archdeacon; Rachel N Shaffer; Wolfgang C Winkelmayer; Ronald J Falk; Prabir Roy-Chaudhury
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

7.  Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Jyotirmoy Dey; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-03-09       Impact factor: 6.577
  7 in total
  3 in total

Review 1.  Mineral and Electrolyte Disorders With SGLT2i Therapy.

Authors:  Giuseppe Cianciolo; Antonio De Pascalis; Irene Capelli; Lorenzo Gasperoni; Luca Di Lullo; Antonio Bellasi; Gaetano La Manna
Journal:  JBMR Plus       Date:  2019-11-04

Review 2.  Kidney disease trials for the 21st century: innovations in design and conduct.

Authors:  William G Herrington; Natalie Staplin; Richard Haynes
Journal:  Nat Rev Nephrol       Date:  2019-10-31       Impact factor: 28.314

Review 3.  New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.

Authors:  Hiddo J L Heerspink; James List; Vlado Perkovic
Journal:  Diabetes Obes Metab       Date:  2018-10       Impact factor: 6.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.